(Q36681338)

15 August 2017

1 reference

title

Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension (English)

1 reference

15 August 2017

Robyn J Barst

1

1 reference

PubMed ID

17163810

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

8

1 reference

15 August 2017

1

1 reference

15 August 2017

95-109

1 reference

Primary pulmonary hypertension. A national prospective study

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Risk factors for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Primary pulmonary hypertension in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Outcomes in children with idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Endothelin system: the double-edged sword in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.1.95

21 January 2018

Identifiers

DOI

10.1517/14656566.8.1.95

1 reference

15 August 2017

1 reference

PubMed ID

17163810